Physician profile
Holly K Miller
NPI 1083841191
$131,954.44
in general payments reported to CMS, 2019-2025
13 companies · $64K in 2025
The $64K reported for 2025 was more than what 97% of Pediatric Hematology-Oncology providers received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $194 · 2021: $4,273 · 2022: $8,242 · 2023: $24K · 2024: $32K · 2025: $64K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $55K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $50K · Travel and Lodging: $11K · Food and Beverage: $3,708 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $55,060.86 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $49,648.00 |
| Travel and Lodging | $10,752.94 |
| Food and Beverage | $3,708.23 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $117,071.64 | 2021-2025 | Joenja, Ruconest |
| Sobi, INC | $13,862.44 | 2023-2025 | |
| Csl Behring | $482.47 | 2023-2025 | Hizentra |
| Takeda Pharmaceuticals U.S.A., INC. | $138.66 | 2024-2025 | Hyqvia, Cuvitru |
| Medtronic Vascular, INC. | $116.07 | 2019 | |
| Novartis Pharmaceuticals Corporation | $101.49 | 2019-2021 | |
| Vertex Pharmaceuticals Incorporated | $63.83 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $40.09 | 2025 | |
| Amgen INC. | $31.25 | 2025 | Actimmune |
| Adma Biomanufacturing LLC | $25.86 | 2023 | |
| Jazz Pharmaceuticals INC. | $20.64 | 2025 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Holly Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.